Jump to content

Laura Niklason

From Wikipedia, the free encyclopedia

Laura Elizabeth Niklason is a physician, professor and internationally recognized researcher in vascular and lung tissue engineering. She is the Nicholas M. Greene Professor of Anesthesiology and Biomedical Engineering at Yale University[1] and co-founder, chief executive officer and president of Humacyte, a regenerative medicine company developing bioengineered human tissues.[2]

Her work on lab-grown lungs was recognized as one of the top 50 most important inventions of 2010 by Time magazine.[3][4] Niklason was included on Fortune’s “Digital Health Care Leaders” list in 2017 for her work in regenerative medicine.[5]

Niklason was inducted into the National Academy of Inventors in 2014.[6] In 2015, she was elected to the National Academy of Medicine.[7] In 2020, Niklason was elected a member of the National Academy of Engineering for cardiovascular tissue engineering, lung regeneration, and biomedical imaging.[8][9] She holds more than 30 issued or pending patents in the United States.

Early life and education

[edit]

Laura Niklason was born in Evanston, Ill. She earned a B.S. in physics and a B.A. in biophysics from the University of Illinois (Urbana-Champaign campus) in 1983. She holds an M.D. from the University of Michigan and a Ph.D. in biophysics from the University of Chicago. Niklason completed her medical training in anesthesiology and critical care medicine at Massachusetts General Hospital in 1996.[10]

Career

[edit]

Niklason was a faculty member at Duke University from 1998 to 2005.[1] In 2004, Niklason along with Drs. Shannon Dahl and Juliana Blum, co-founded Humacyte, a company based in Durham, North Carolina, that is pioneering the development and manufacture of off-the-shelf, universally implantable, bioengineered human tissues to improve the lives of patients and transform the practice of medicine.[2][11] In 2006, Niklason joined the faculty at the Yale School of Medicine, where she currently serves as an adjunct professor of anesthesia and biomedical engineering.[12]

In 2010, Niklason and her colleagues were able to successfully produce an engineered rat lung that could inhale and exhale carbon dioxide.[13] In 2013, Niklason along with Duke researcher Dr. Jeffery Lawson, developed a bioengineered blood vessel, which Lawson grafted into an artery in a Duke patient's arm.[14]

In 2016, Niklason was named as the Nicholas M. Greene Professor of Anesthesiology and Biomedical Engineering at Yale.[15] As part of a research team, Niklason conducted clinical trials into the effectiveness of giving patients experiencing kidney failure bioengineered blood vessels.[16]

In 2020, Niklason was appointed CEO and president of Humacyte.[17] Under Niklason’s leadership, the company went public through a merger with Alpha Healthcare Acquisition Corp in 2021.[18][19][20][21]

Niklason, a renowned world leader in cellular therapies and regenerative medicine, continues to maintain an active scientific laboratory, and speaks globally on her research in vascular and non-vascular tissue engineering.

Philanthropy

[edit]

The Brady W. Dougan and Laura E. Niklason House at University of Chicago was named for her.[22]

Awards and honors

[edit]

Niklason is the recipient of multiple awards and honors, including:

  • 2021: Named one of FiercePharma's 2021 Fiercest Women in Biotech.[23]
  • 2021: Winner of Triangle Business Journal 2021 Life Sciences Award. Award went to Humacyte, Inc., of which Niklason is the founder.[24]
  • 2020: National Academy of Engineering Member[8]
  • 2017: Named to Fortune's Digital Health Care Leaders list for her work in regenerative medicine.[5]
  • 2017: Cotlove Lectureship Award in Laboratory Medicine[25]
  • 2017: Inducted into Women in Technology Hall of Fame[26]
  • 2016: Named to 2016 Disruptor 50 Companies. Award went to Humacyte, Inc., of which Niklason is the founder.[27]
  • 2015: Winner of FierceMedicalDevices 2016 Fierce 15. Award went to Humacyte, Inc., of which Niklason is the founder.[28]
  • 2014: National Academy of Inventors Fellow[6]
  • 2011: Winner of Popular Mechanics Breakthrough Innovators Award for 2011, for development of "off-the-self" tissue engineered vascular graft to treat patients with vascular disease. Award went to Humacyte, Inc., of which Niklason is the founder.[29]
  • 2011: Winner of Frost & Sullivan Growth, Innovation & Leadership Award 2011, for development of engineered vascular graft. Award went to Humacyte, Inc., of which Niklason is founder.
  • 2010: 50 best inventions of 2010 (engineered lung) Time[4]
  • 2008: College of Fellows, American Institute for Medical and Biological Engineering (AIMBE)[30]
  • 2002: Beeson Physician Scholars Award, American Federation for Aging Research
  • 2001: One of 21 U.S. News & World Report Innovators for 2001
  • 2001: Hunt scholar, Pratt School of Engineering, Duke University
  • 2000: Discover magazine award for technological innovation (finalist in the health category)
  • 2000: Selected by the National Academy of Engineering for Symposium on Frontiers of Engineering[31]
  • 1999: “Eminent Scientist of the Year,” International Research Promotion Council

Publications

[edit]

Niklason is the co-author of more than 120 publications. A selected list follows:

References

[edit]
  1. ^ a b "Laura Niklason, PhD, MD". medicine.yale.edu. Retrieved September 21, 2021.
  2. ^ a b "Company". HUMACYTE. Retrieved September 21, 2021.
  3. ^ Staff. "The Entrepreneurs". PharmaVOICE. Retrieved August 6, 2018.
  4. ^ a b Park, Alice (November 11, 2010). "The 50 Best Inventions of 2010 - TIME". Time. ISSN 0040-781X. Retrieved September 21, 2021.
  5. ^ a b "34 Leaders Who Are Changing Health Care". Fortune. Retrieved September 21, 2021.
  6. ^ a b "National Academy of Inventors". Retrieved September 21, 2021.
  7. ^ anonymous. "Prof. Laura Niklason Elected To The National Academy of Medicine". Yale School of Engineering & Applied Science. Retrieved September 21, 2021.
  8. ^ a b anonymous. "Laura Niklason Elected To The National Academy of Engineering". Yale School of Engineering & Applied Science. Retrieved September 21, 2021.
  9. ^ "Dr. Laura Elizabeth Niklason". United States National Academy of Engineering. Retrieved October 9, 2023.
  10. ^ "Organizer/Speaker- Cell Symposia: Engineering Organoids and Organs". www.cell-symposia.com. Retrieved September 21, 2021.
  11. ^ "Executive Voice: Her Durham firm pioneers transformation of medicine". www.bizjournals.com. Retrieved September 21, 2021.
  12. ^ "Lab Members". medicine.yale.edu. Retrieved September 21, 2021.
  13. ^ Petersen, Thomas H.; Calle, Elizabeth A.; Zhao, Liping; Lee, Eun Jung; Gui, Liqiong; Raredon, MichaSam B.; Gavrilov, Kseniya; Yi, Tai; Zhuang, Zhen W.; Breuer, Christopher; Herzog, Erica (July 30, 2010). "Tissue-Engineered Lungs for in Vivo Implantation". Science. 329 (5991): 538–541. Bibcode:2010Sci...329..538P. doi:10.1126/science.1189345. ISSN 0036-8075. PMC 3640463. PMID 20576850.
  14. ^ "Surgeons at Duke University Hospital Implant Bioengineered Vein". Duke Health. June 6, 2013. Retrieved September 21, 2021.
  15. ^ Staff (January 6, 2016). "Dr. Laura Niklason appointed the Nicholas Greene Professor". Yale News. Retrieved August 6, 2018.
  16. ^ Xie, Abigail. "Bioengineered blood vessels shown to be effective in patients with kidney failure". The Chronicle. Retrieved August 6, 2018.
  17. ^ "Humacyte Appoints Founder Laura Niklason MD, PhD as President and Chief Executive Officer". www.businesswire.com. November 20, 2020. Retrieved September 21, 2021.
  18. ^ "Humacyte Announces Successful Closing of Business Combination with Alpha Healthcare Acquisition Corp. | Humacyte, Inc". humacyte.gcs-web.com. Retrieved September 21, 2021.
  19. ^ Franklin, Rebecca Spalding, Joshua (February 17, 2021). "Human tissue developer Humacyte agrees to SPAC merger to go public". Reuters. Retrieved September 21, 2021.{{cite news}}: CS1 maint: multiple names: authors list (link)
  20. ^ "Did You Expect It Would Take This Long To Go Public?". www.lifescienceleader.com. Retrieved September 21, 2021.
  21. ^ "Pioneering regenerative med scientist Laura Niklason takes her company public in the latest big SPAC deal. And that gives her a shot at making biotech history". Endpoints News. Retrieved September 21, 2021.
  22. ^ "Brady W. Dougan and Laura E. Niklason House | The University of Chicago Campaign: Inquiry and Impact". campaign.uchicago.edu. Retrieved August 8, 2018.
  23. ^ "FiercePharma 2021 Fiercest Women: Laura Niklason, Humacyte". www.fiercepharma.com. November 15, 2021. Retrieved November 15, 2021.
  24. ^ "2021 Life Sciences Awards: Humacyte". www.bizjournals.com. Retrieved September 21, 2021.
  25. ^ "Previous Award Winners". ACLPS. Retrieved September 21, 2021.
  26. ^ "WITI - Laura Niklason, M.D., Ph.D." www.witi.com. Retrieved September 21, 2021.
  27. ^ CNBC (June 7, 2016). "2016 CNBC's Disruptor 50". www.cnbc.com. Retrieved September 21, 2021.
  28. ^ "Humacyte". FierceBiotech. January 23, 2017. Retrieved September 21, 2021.
  29. ^ Ward, Logan; Mechanics, the Editors of Popular (October 3, 2011). "11 Brilliant Innovators: Breakthrough Awards 2011". Popular Mechanics. Retrieved September 21, 2021. {{cite web}}: |first2= has generic name (help)
  30. ^ "Laura E. Niklason, MD. Ph.D. COF-0809 - AIMBE". Retrieved September 21, 2021.
  31. ^ Read "Frontiers of Engineering: Reports on Leading-Edge Engineering From the 2000 NAE Symposium on Frontiers in Engineering" at NAP.edu. 2001. doi:10.17226/10063. ISBN 978-0-309-07319-6.